247Wallst·2026-03-12 14:46Core Viewpoint - Hims & Hers has transitioned from compounded GLP-1 drugs to selling branded Wegovy and Ozempic directly, resolving legal issues and restoring investor confidence, leading to a significant stock price rebound of 64% since the announcement [1][2] Group 1: Company Developments - Hims & Hers agreed to sell branded Wegovy and Ozempic while discontinuing most compounded GLP-1 advertising, resolving a patent lawsuit with Novo Nordisk [1] - The company had seen its shares drop over 75% due to regulatory scrutiny and legal challenges but has now regained legitimacy with the new distribution rights [1] - The pivot to branded products enhances Hims' credibility as a healthcare partner and removes concerns about counterfeit safety and patent violations [1] Group 2: Market Response - Following the announcement, Hims' stock surged by 64%, including a remarkable 40% gain in a single day [1] - Analysts have responded positively, with Needham upgrading its rating to Buy with a target price of $30, while other firms have raised their price targets [1] - Revenue projections for Hims are robust, with expectations of $2.35 billion in 2025, reflecting a 59% year-over-year increase [1] Group 3: Risks and Challenges - Despite the positive developments, Hims is now heavily reliant on Novo Nordisk as a single supplier for its growth, which poses risks if production issues arise or if Novo changes its strategy [1][2] - The stock's current valuation is high, and analysts caution that any issues with patient retention or slower adoption of branded products could negatively impact share prices [1] - Historical context shows that previous collaborations with Novo have faced challenges, raising concerns about the sustainability of the current partnership [1]